Novel blood diagnostic for rapid bacterial pathogen identification and AMR
Severe bacterial infections require urgent, targeted treatment – but current diagnostic methods often rely on slow culture-based testing. These delays can lead to the wrong antibiotic being prescribed, driving antimicrobial resistance (AMR) and worsening patient outcomes.
GenomeKey is developing a next‑generation IVD blood test that rapidly identifies bacterial pathogens and determines antimicrobial resistance profiles directly from a blood sample. By eliminating the need for bacterial culture, GenomeKey can map the right antibiotic to the right patient in just 7 hours.
This approach has the potential to transform infection management. Faster, more precise diagnosis enables earlier targeted treatment, reduces inappropriate antibiotic use and supports NHS systems to combat rising AMR.
To support development, our HRC:
- Helped position GenomeKey as a high‑impact diagnostic innovation tackling AMR
- Connected the team with NHS partners to understand infection‑management needs and pathways
- Supported real‑world evaluation and clinical integration within NHS services
- Enabled evidence generation to accelerate adoption and demonstrate clinical value
